Drug: Oxycodone: chronic pain clinical trials

Registry records that list "Drug: Oxycodone" as an intervention. Being studied does not mean an intervention works or is approved.

Trials with Canadian sites

Recruiting in Canada

Registry records in total

Trials in Canada

No trial with a Canadian site lists this intervention in this snapshot.

Trials worldwide (outside Canada)

10 trials, 0 recruiting or not yet recruiting. Recruiting first.

		Phase	Countries
QLB After Nephrectomy NCT03529201	Completed	Not applicable	Poland	Medical University of Lublin	2018-05-07
To Demonstrate Equivalence in Analgesic Efficacy & Bowel Function Between OXN PR Higher Dose & Lower Dose Tablet Strengths in Subjects With Non-cancer or Cancer Pain NCT02321397	Completed	Phase 2, Phase 3	Germany	Mundipharma Research GmbH & Co KG	2014-11
Determine the Safety and Efficacy of Oxy/Nal Tablets Compared to Oxy PR in Subjects With Cancer Pain NCT01885182	Completed	Phase 3	China	Mundipharma (China) Pharmaceutical Co. Ltd	2013-06-01
Evaluation of the Tolerability of Switching Subjects on Chronic ATC Opioid Therapy to Buprenorphine HCl Buccal Film NCT01871285	Completed	Phase 2	United States	BioDelivery Sciences International	2013-06
Evaluation of the Efficacy and Tolerability of Etoricoxib Monotherapy Versus Combination Oxycodone-etoricoxib in Moderate to Severe Pain From Chronic Low Back Pain NCT01344720	Unknown status	Phase 4	Italy	Azienda Sanitaria Locale 4, Teramo	2011-05
Prospective Study About Clinical and Pharmacogenetic Safety of Opioid Use for Chronic Pain NCT00916890	Suspended	Phase 4	Italy	Fondazione IRCCS Policlinico San Matteo di Pavia	2009-02
Opioid Treatment for Chronic Low Back Pain and the Impact of Mood Symptoms NCT01502644	Completed	Phase 4	United States	Brigham and Women's Hospital	2009-02
A Study Comparing Oxycodone to Oxycodone/Naloxone in Moderate to Severe, Chronic Cancer Pain NCT00513656	Completed	Phase 2	United Kingdom	Mundipharma Research GmbH & Co KG	2007-09
Tapentadol (CG5503) NCT00421928	Completed	Phase 3		Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	2007-01
A Study of the Effectiveness and Safety of Sustained-release Hydromorphone (a Strong Opioid) in Patients With Chronic Noncancer Pain. NCT00261495	Completed	Phase 3	Czechia, Denmark, France, Germany and 6 more	Janssen Pharmaceutica N.V., Belgium	2006-03

Conditions studied with this intervention

Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status.